



ELSA U. PARDEE FOUNDATION

■ 2011 ANNUAL REPORT ■

Fighting Cancer Every Day

OFFICERS AND TRUSTEES

Gail E. Lanphear	President
Lisa J. Gerstacker	Vice President, Asst. Treasurer
*James A. Kendall	Secretary
**Mary M. Neely	Secretary
Alan W. Ott	Treasurer
W. James Allen	Asst. Treasurer, Asst. Secretary
Laurie G. Bouwman	Trustee
***William C. Lauderbach	Trustee
William D. Schuette	Trustee
Michael Woolhiser	Trustee

Lucille M. Dougherty, Staff Assistant

* Resigned as Secretary & Trustee, December 9, 2011

** Elected as Secretary, December 9, 2011

*** Elected as Trustee, December 9, 2011

THE MEDICAL COMMITTEE

Michael Woolhiser, Ph.D. (Chairman)

Darrell R. Boverhof, Ph.D.

Brian B. Gourlie, Ph.D.

Matthew J. LeBaron, Ph.D.

Patricia LoRusso, Ph.D.

*Cindy K. Miranti, Ph.D.

David H. Swenson, Ph.D.

Bing Yang, Ph.D.

* Resigned, November 8, 2011

PURPOSE OF THE FOUNDATION

The Elsa U. Pardee Foundation was established in 1944 under the terms of the will of its namesake, whose life was taken by cancer on October 2, 1944. Mrs. Pardee provided a \$1,000,000 trust fund “for the promotion of the control and cure of cancer.” She directed that this bequest be used to support research in the field of cancer and to provide for others the advantages of knowledge and techniques still undiscovered in the treatment of cancer.

Cover Photo

Elsa U. Pardee with her husband, James T. Pardee, former board chairman of The Dow Chemical Company.

PRESIDENT'S LETTER

We offer a very special salute this year to James A. Kendall, who retired during the year after 40 years of service to the Foundation, serving most of those years as its secretary. Forty years is a very long time, and must set some kind of longevity record for a voluntary position of this kind. Jim's service has always been exemplary, and we will miss his steady influence and quiet leadership, more, I believe, than we realize. A special dinner was held to honor Jim's outstanding contributions to the Foundation, and to bid him a fond farewell.

We are pleased, on the other hand, to welcome the newest addition to the board of trustees, William Lauderbach. Bill is the new president of the Midland/Gladwin Pardee Treatment Committee.


The Committee and the Foundation suffered a great loss during the year with the death of Sandra Schreiber, a 35-year employee of the Midland/Gladwin Pardee Treatment Committee. Her outstanding efforts will be long remembered.

Aside from these personnel changes, the Foundation continued faithfully its mission to fund cancer research and to provide assistance to victims of cancer in six counties of Michigan and Texas. Cancer research grants totaling \$2,549,004 were awarded during the year. Cancer victims in Michigan received some \$1,125,000 in aid from the Foundation during the year.

We are estimating our 2012 giving at \$3,700,000, about the same level as a year ago.

I extend my gratitude for their efforts once again to our highly esteemed Medical Committee members, who recommend outreach choices, and to my devoted fellow trustees.

Sincerely,



Gail E. Lanphear
President

Grants Made By The Foundation For the Year Ended December 31, 2011

Recipient and Purpose	Amount
University of Chicago – For the study of non-invasive delivery of stem cells as therapeutic vehicles to the brain tumors.	\$125,000
Children's Hospital Boston – For the study of the development of a short peptide therapeutic with anti-tumor and anti-metastatic activity.	162,500
University of Cincinnati – For the study of an efficient targeted strategy against endocrine-resistant and triple-negative breast cancer.	125,000
Florida State University – For the study of phosphoprotein signatures of human triple-negative breast cancer.	93,750
University of Kentucky – For the study of light-activated ruthenium complexes as a new class of selective and modular chemotherapeutic agents.	118,003
Michigan State University – For the study of elucidation and targeting of novel signaling pathways essential for breast cancer metastasis (\$128,769); for the study of using bioinformatic methods to dissect tumor development and develop therapy (\$138,431); for the study of oligo-deoxynucleotides (ODNs) directed against Fra1/Ap-1: multi stage tools against breast cancer (\$114,186).	381,386
University of Michigan – For pilot studies on the anti-tumor capacity of novel catalytic nanoparticles (\$137,376); for the study of TRPV3 Ca2+ channel as a novel target of epithelial cancers (\$120,000); for the study of immunotherapy of melanoma utilizing cancer stem cell-based vaccines (\$123,346); for support of a medical oncology fellowship training program (\$100,000).	480,722
New York University School of Medicine – For the study of novel epigenetic regulators for melanoma therapy.	178,199
Penn State College of Medicine – For the study of targeting of cellular energy metabolism as novel anticancer therapy.	125,000
Pennsylvania State University – For the study of novel thiobarbituric acid compounds for drug resistant brain tumors.	125,000
University of Pittsburgh – For the study of therapeutic micro-needle patch vaccines against tumor blood cells.	100,000
Purdue University – For the study of Plk1 in chemoresistance of cancer.	125,000
Roswell Park Alliance – For the study of developing a high-throughput approach to making personalized therapeutic anticancer vaccines.	62,500
St. Mary's of Michigan – For the study of the effects of exercise and donepezil on cognitive impairment during chemotherapy treatment: a pilot study.	15,000
The University of Texas, M.D. Anderson Cancer Center – For the study of understanding off-target effects of BRAF inhibitors in melanoma and epithelial cells.	157,288
Virginia Commonwealth University – For the study of the role of MDA-9/syntenin in head and neck squamous cell carcinoma progression.	125,000
University of Virginia – For the study of bivalent domains identify novel cancer stem cell genes in neuroblastoma.	104,442

Wayne University – For the study of CXCR2 signaling complex in endothelial progenitor cell tumor neovascularization (\$134,234); for the study toward high-sensitivity tumor detection with magnetic resonance imaging using new PARACEST agents (\$149,312).	283,546
University of Wisconsin – For the study of novel combination therapy for prostate cancer.	154,250
Yale University – For the study of treating lymphoma by targeting microRNAs (\$133,337); for the study of pre-clinical evaluation of IGFBP7 as a lung cancer therapeutic (\$100,000).	233,337
MidMichigan Medical Center – For continuation of the cancer registry (\$58,000); for the memorial lectureship program (\$6,500).	64,500
Pardee Cancer Treatment Association of Greater Brazosport, TX – For a program supporting the cure and control of cancer.	50,000
Pardee Cancer Treatment Fund of Midland/Gladwin – To assist in the cure and control of cancer through the program of the Pardee Cancer Treatment Fund.	400,000
Pardee Cancer Treatment Fund of Bay County – To assist in the cure and control of cancer through the program of the Pardee Cancer Treatment Committee of Bay County.	150,000
Pardee Cancer Treatment Fund of Clare County – To assist in the cure and control of cancer through the program of the Pardee Cancer Treatment Committee of Clare County.	150,000
Pardee Cancer Treatment Fund of Gratiot County – To assist in the cure and control of cancer through the program of the Pardee Cancer Treatment Committee of Gratiot County.	175,000
Pardee Cancer Treatment Fund of Isabella County – To assist in the cure and control of cancer through the program of the Pardee Cancer Treatment Committee of Isabella County.	200,000
Council of Michigan Foundations	8,400
Total Grants	<u>\$4,472,823</u>
Decrease in grants authorized but unpaid	(798,819)
Grant funds returned	(221,022)
Administrative expenses	221,418
Federal Excise Tax	47,000
Other Taxes	12,252
TOTAL DISBURSEMENTS	<u>\$3,733,652</u>

ELSA U. PARDEE FOUNDATION

Midland, Michigan

Statement of Assets, Liabilities and Net Assets – Modified Cash Basis

December 31, 2011

Assets

Cash and cash equivalents	\$ 5,320,731
Marketable securities (at fair market value):	
Dow Chemical Co. stock (500,000 shares)	14,380,000
Chemical Financial Corp. stock (61,710 shares)	1,315,657
Stocks - other	31,383,151
Corporate bonds	8,451,259
Foreign bonds	1,335,300
Government bonds	11,011,516
Certificates of deposit	240,068
Mutual funds	1,978,407
Total marketable securities	70,095,358
Limited partnerships	147,027
Prepaid federal excise tax	73,193
Total assets	<u>\$ 75,636,309</u>
<u>Unrestricted net assets</u>	<u>\$ 75,636,309</u>
Total unrestricted net assets	<u>\$ 75,636,309</u>

Statement of Revenue, Expenses, and Changes in Net Assets – Modified Cash Basis

Year ended December 31, 2011

Revenues and gains (losses)

Interest	\$ 749,679
Dividends	1,467,426
Net realized gain on investments	2,602,873
Net unrealized loss on investments	(8,546,825)
Loss from limited partnership	(13,158)
Total revenue and gains (losses)	<u>(3,740,005)</u>

Grants

Grants authorized:

Grant payments made	4,472,823
Grant funds returned	(221,022)
Decrease in grants authorized but unpaid	(798,819)
Total grants	<u>3,452,982</u>

Other expenses

Administrative	221,418
Federal excise taxes	47,000
Other taxes	12,252
Total other expenses	<u>280,670</u>
Total grants and other expenses	<u>3,733,652</u>
Decrease in unrestricted net assets	(7,473,657)
Unrestricted net assets at beginning of period	83,109,966
Unrestricted net assets at end of period	<u>\$ 75,636,309</u>

GRANT APPLICATION PROCEDURE

The Elsa U. Pardee Foundation operates under the laws of the State of Michigan, with headquarters in Midland, Michigan. Since its establishment (the Articles of Incorporation were filed December 28, 1944), the trustees have been responsible for allocating the funds to the best uses for which the late Mrs. Pardee intended them.

The Foundation does not directly administer the programs which it supports. The recipients are asked to submit yearly progress reports and a financial accounting concerning the expenditures of the research grant.

Grants are limited under the terms of the charter to the cure and control of cancer, and in general do not provide for building funds, equipment (except that used in a specific project), fellowships or fund-raising campaign contributions.

The Elsa U. Pardee Foundation provides support for research directed towards the detection, treatment, and cure of cancer. Priority is given to researchers at non-profit institutions in the United States who are new to the field of cancer research, or to established research investigators examining new approaches to cancer cure.

An attempt is made to initiate several new projects each year, as other projects are concluded. The Foundation particularly welcomes innovative, small-scale, short-term projects which may be difficult to fund elsewhere until some interesting results are obtained.

Elsa U. Pardee Foundation
P.O. Box 2767
Midland, Michigan 48641-2767

Telephone: (989) 832-3691

Website: www.pardeefoundation.org

ELSA U. PARDEE
FOUNDATION

2011 ANNUAL REPORT

Correspondence may be addressed to:

THE ELSA U. PARDEE FOUNDATION

P.O. Box 2767

Midland, MI 48641-2767

Phone: 989.832.3691

Fax: 989.832.8842

Website: www.pardeefoundation.org